Hemogenyx Pharmaceuticals PLC on Monday reported the opening of the first clinical site in its HG-CT-1 phase 1 trial.
The London-based biotechnology company has so far focused on preclinical-stage treatment, but the new site marks ‘a major milestone’ in advancing its lead asset to clinical testing.
Hemogenyx is currently recruiting patients to trial HG-CT-1, a drug designed to treat acute myeloid leukaemia. This is the most common form of acute leakaemia in adults and at present, is treated with chemotherapy. Its survival rate is low, with less than 30% of diagnosed adults surviving five years.
Hemogenyx’s drug is a form of chimeric antigen receptor T-cell therapy, which modifies the body’s immune cells to identify and kill cancer cells.
Dr Vadislav Sandler, chief executive officer and co-founder of Hemogenyx, said: ‘The opening of our first clinical site for the phase I trial of HG-CT-1 is a milestone in our mission to revolutionise the treatment landscape for relapsed and refractory acute myeloid leukaemia. This trial offers hope to patients who currently face limited treatment options by exploring the safety and potential efficacy of HG-CT-1.’
Hemogenyx shares were up 0.3% at 392.75 pence each on Monday afternoon in London.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
